Pancreatic Cancer Research

ResearcherJiangsu Province HospitalNo recent work listed

Taoyue Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6375-3622; OpenAlex author ID A5100733941, A5113171340. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2021: 4 papers · 2022: 4 papers

Papers 8

  1. Metabolomics study reveals systematic metabolic dysregulation and early detection markers associated with incident pancreatic cancer. Co-author DOI 10.1002/ijc.33877↗
  2. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  3. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. First author DOI 10.1186/s12943-022-01636-3↗
  4. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  5. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  6. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. First author DOI 10.1186/s12943-021-01333-7↗
  7. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  8. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.800268↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peng Shen · 7 shared papers, 2021–2022 · strength 0.87
  2. Kuirong Jiang · 7 shared papers, 2021–2022 · strength 0.87
  3. Qun Chen · 6 shared papers, 2021–2022 · strength 0.75
  4. Hao Yuan · 6 shared papers, 2021–2022 · strength 0.75
  5. Lingdong Meng · 5 shared papers, 2021–2022 · strength 0.61
  6. Wanli Ge · 4 shared papers, 2021–2022 · strength 0.50
  7. Zipeng Lu · 4 shared papers, 2021–2022 · strength 0.49
  8. Xumin Huang · 4 shared papers, 2021–2022 · strength 0.48
  9. Yi Miao · 4 shared papers, 2021–2022 · strength 0.48
  10. Pengfei Wu · 3 shared papers, 2021–2022 · strength 0.39
  11. Pengfei Wu · 3 shared papers, 2021–2022 · strength 0.36
  12. Yi Miao · 2 shared papers, 2022 · strength 0.27
  13. Baobao Cai · 2 shared papers, 2021–2022 · strength 0.25
  14. Guodong Shi · 1 shared paper, 2022 · strength 0.13
  15. Min Tu · 1 shared paper, 2022 · strength 0.13
  16. Shouji Cao · 1 shared paper, 2021 · strength 0.12
  17. Jingjing Zhang · 1 shared paper, 2021 · strength 0.12
  18. Qun Chen · 1 shared paper, 2021 · strength 0.12
  19. Qiang Li · 1 shared paper, 2022 · strength 0.09
  20. Shuangyuan Wang · 1 shared paper, 2022 · strength 0.09
  21. Jiajun Zhao · 1 shared paper, 2022 · strength 0.09
  22. Donghui Li · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.